WHAT IS THE PURPOSE OF DRUG TRIALS SNAPSHOTs?

Drug Trials Snapshots provide consumers with information about who participated in clinical trials that supported the FDA approval of new drugs. The information provided in these Snapshots also highlights whether there were any differences in the benefits and side effects among sex, race and age groups. Drug Trials Snapshots is part of an overall FDA effort to make demographic data more available and transparent.

HOW TO USE SNAPSHOTs:

Each Snapshot includes contains information about the drug in a question and answer format. At the end of each section of the Snapshot, there is a shaded bar with the words “MORE INFO”. Click the “MORE INFO” bar for more technical and detailed content. At the bottom of each Snapshot, there is a link to the drug’s Package Insert as well as the medical review.

LIMITATIONS OF SNAPSHOTs:

The Snapshot is intended as one tool for consumers to use when discussing a drug’s risks and benefits with their physician. Do not rely on Snapshots alone to make decisions regarding medical care. Do not use Snapshots to substitute for advice from your health care professional. Conclusions regarding how effective and safe a drug is among different sex, race, and age groups cannot always be made, often because the numbers of patients in some groups are too limited to allow for meaningful comparisons to other groups and to the overall results.

VISIT DRUG TRIALS SNAPSHOTs:

www.fda.gov/DrugTrialsSnapshots
In this section you will find resources that each of FDA’s three main audience groups use most often to answer regulatory and drug-related questions. Audience-specific resources pages are focused on information that a specific type of user, such as a consumer, may want to find. It is not intended to be an all-inclusive list, but instead serves as a guide to key information. We appreciate feedback about what content you would find most useful on these resource pages.

RESOURCES AVAILABLE:

**Consumer-friendly information**
- Medication Guides
  *Information for patients on how to safely use certain drugs*

**Approval, labeling, side effects, and safety information**
- Drug Trials Snapshots
  *Information about who participated in the clinical trials for new FDA approved drugs*

- Drugs@FDA
  *Information on FDA-approved brand name and generic drugs including labeling and regulatory history*

- Drugs with Approved Risk Evaluation and Mitigation Strategies (REMS)
  *REMS is a risk management plan required by FDA for certain prescription drugs, that uses tools beyond routine professional labeling to ensure that the benefits of the drug outweigh its risks.*

- Index to Drug-Specific Information
  *List of drugs for which safety alerts or other advisories have been issued*

- New Molecular Entity and New Therapeutic Biological Product Approvals
  *Novel new drugs approved by year*

VISIT RESOURCES FOR YOU:
www.fda.gov/Drugs/ResourcesForYou
Drug Approval-Bringing a New Drug to the Market

A SMALL PHARMACEUTICAL COMPANY REVIEWS THE PATH LEADING TO FDA APPROVAL TO MARKET A NEW DRUG IN THE UNITED STATES

THE FDA CDER DRUG APPROVAL CASE STUDY IS A NEW LEARNING TOOL DESIGNED TO ADVANCE KNOWLEDGE, INSIGHT AND UNDERSTANDING OF FDA'S DRUG REGULATORY PROCESSES.

Who is it for?
• Students and health professionals interested in drug development (including medical and pharmacy students)
• Pharmaceutical and clinical innovators
• Small business staff
• Patients and patient advocacy groups

What does it cover?
The case study guides the reader through the steps of drug development and opportunities for interacting with FDA, including:
• Nonclinical testing
• Investigational New Drug application content and submission
• Clinical trials and protection of human subjects
• New Drug Application content
• FDA inspections of manufacturing and clinical sites
• Post marketing requirements

How can it be used in a classroom environment?
Students read the case study before class. Discussion questions are provided to emphasize the major points of the case study. Exercises, activities and quizzes to reinforce learning are provided.

Is continuing education credit offered?
CME is currently not offered for the case study.

Learning Objectives:
1. State the objectives of the drug development and approval process.
2. Identify the major activities that occur during the drug development and approval process from nonclinical tests through approval from the U.S. Food and Drug Administration (FDA).
3. Describe the major elements and steps to conduct a clinical trial.
4. Apply the drug approval process to a Fictional New Molecular Entity (NME) diabetes drug.

Sample text
“Green and her colleagues now faced the task of beginning the clinical trials needed to obtain approval from the US FDA to market the drug.” “Can you give me a big picture overview of the drug development and approval process?” Soto asked.

VISIT CDERLEARN TO VIEW THE FULL CASE STUDY:
http://www.fda.gov/TrainingForHealthProfessionals/ucm464124.htm
John J. Whyte, M.D., M.P.H., is the Director of Professional Affairs and Stakeholder Engagement (PASE). Dr. Whyte is a board-certified internist. He completed an internal medicine residency at Duke Medical Center and earned a master’s of public health in health policy and management at Harvard University of Public Health. Previously, Whyte served as the Chief Medical Expert at The Discovery Channel.

John.Whyte@fda.hhs.gov
240-402-4121
The sponsor submits an Investigational New Drug (IND) application to FDA based on the results from initial testing that include the drug's composition and manufacturing, and develops a plan for testing the drug on humans.

Drug developed
Drug sponsor develops a new drug compound and seeks to have it approved by FDA for sale in the United States.

Animals Tested
Sponsor must test new drug on animals for toxicity. Multiple species are used to gather basic information on the safety and efficacy of the compound being investigated/researched.

IND Application
The sponsor submits an Investigational New Drug (IND) application to FDA based on the results from initial testing that include the drug's composition and manufacturing, and develops a plan for testing the drug on humans.

IND REVIEW
FDA reviews the IND to assure that the proposed studies, generally referred to as clinical trials, do not place human subjects at unreasonable risk of harm. FDA also verifies that there are adequate informed consent and human subject protection.

Drug Development
The center’s evaluation not only prevents quackery, but also provides doctors and patients the information they need to use medicines wisely. CDER ensures that drugs, both brand name and generic, are effective and their health benefits outweigh their known risks.

FDA’s Center for Drug Evaluation and Research (CDER) evaluates new drugs before they can be sold.

What is a drug as defined by the FDA?
A drug is any product that is intended for use in the diagnosis, cure mitigation, treatment, or prevention of disease; and that is intended to affect the structure or any function of the body.

Drug Approval Process
U.S. Food and Drug Administration
The typical number of healthy volunteers used in Phase 1; this phase emphasizes safety. The goal here in this phase is to determine what the drug’s most frequent side effects are and, often, how the drug is metabolized and excreted.

20-80

IND REVIEW
At the end of Phase 2, FDA and sponsors discuss how large-scale studies in Phase 3 will be done.

Drug Sponsor’s Clinical Studies/Trials

Drug Sponsor’s Discovery and Screening Phase

20-80

The typical number of patients used in Phase 2; this phase emphasizes effectiveness. This goal is to obtain preliminary data on whether the drug works in people who have a certain disease or condition. For controlled trials, patients receiving the drug are compared with similar patients receiving a different treatment—usually a placebo, or a different drug. Safety continues to be evaluated, and short-term side effects are studied.

100’s

At the end of Phase 2, FDA and sponsors discuss how large-scale studies in Phase 3 will be done.

1000’s

The typical number of patients used in Phase 3. These studies gather more information about safety and effectiveness, study different populations and different dosages, and uses the drug in combination with other drugs.

1000’s
Who reviews new drug submissions?
A team of CDER physicians, statisticians, chemists, pharmacologists, and other scientists review the drug sponsor’s data and proposed labeling of drugs.

What other drug products are regulated by FDA?
Drugs include more than just medicines. For example, fluoride toothpastes, antiperspirants (not deodorant), dandruff shampoos, and sunscreens are all considered drugs.

Drug Labeling
FDA reviews the drug’s professional labeling and assures appropriate information is communicated to health care professionals and consumers.

Application Reviewed
After an NDA is received, FDA has 60 days to decide whether to file it so it can be reviewed. If FDA files the NDA, the FDA Review team is assigned to evaluate the sponsor’s research on the drug’s safety and effectiveness.

NDA Application
The drug sponsor formally asks FDA to approve a drug for marketing in the United States by submitting an NDA. An NDA includes all animal and human data and analyses of the data, as well as information about how the drug behaves in the body and how it is manufactured.

Review Meeting
FDA meets with a drug sponsor prior to submission of a New Drug Application.

Facility Inspection
FDA inspects the facilities where the drug will be manufactured.

Drug Approval
FDA reviewers will approve the application or issue a response letter.

FASTER APPROVALS
The Accelerated Approval program allows earlier approval of drugs that treat serious diseases and that fill an unmet medical need. The approval is faster because FDA can base the drug’s effectiveness on a "surrogate endpoint" such as a blood test or X-ray result, rather than waiting for results from a clinical trial.

The Fast Track program helps reduce the time for FDA’s review of products that treat serious or life-threatening diseases and those that have the potential to address an unmet medical need. Drug sponsors can submit portions of an application as the information becomes available ("rolling submission") instead of having to wait until all information is available.

PDUFA
Prescription Drug User Fee Act
Since the PDUFA was passed in 1992, more than 1,000 drugs and biologics have come to the market, including new medicines to treat cancer, AIDS, cardiovascular disease, and life-threatening infections.

FDA’s Post-Approval Risk Assessment Systems
Because it’s not possible to predict all of a drug’s effects during clinical trials, monitoring safety issues after drugs get on the market is critical. The role of FDA’s post-marketing safety system is to detect serious unexpected adverse events and take definitive action when needed.

Once FDA approves a drug, the post-marketing monitoring stage begins. The sponsor (typically the manufacturer) is required to submit periodic safety updates to FDA.

FDA’s MedWatch voluntary system makes it easier for physicians and consumers to report adverse events. Usually, when important new risks are uncovered, the risks are added to the drug’s labeling and the public is informed of the new information through letters, public health advisories, and other education. In some cases, the use of the drug must be substantially limited. And in rare cases, the drug needs to be withdrawn from the market.

www.fda.gov/medwatch
(800) FDA-1088 (322-1088) phone
(800) FDA-0178 (322-0178) fax

NDA REVIEW
FDA’s New Drug Application (NDA) Review

FAST APPROVALS
The Accelerated Approval program allows earlier approval of drugs that treat serious diseases and that fill an unmet medical need. The approval is faster because FDA can base the drug’s effectiveness on a “surrogate endpoint” such as a blood test or X-ray result, rather than waiting for results from a clinical trial.

The Fast Track program helps reduce the time for FDA’s review of products that treat serious or life-threatening diseases and those that have the potential to address an unmet medical need. Drug sponsors can submit portions of an application as the information becomes available (“rolling submission”) instead of having to wait until all information is available.

Drug Approval
FDA reviewers will approve the application or issue a response letter.

PDUFA
Prescription Drug User Fee Act
Since the PDUFA was passed in 1992, more than 1,000 drugs and biologics have come to the market, including new medicines to treat cancer, AIDS, cardiovascular disease, and life-threatening infections.

Page 2